
EquityIndex FundsVery High Risk
Regular
NAV (09-Oct-26)
Returns (Since Inception)
Fund Size
₹200 Cr
Expense Ratio
1.10%
ISIN
INF754K01LR3
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+15.35%
— (Cat Avg.)
3 Years
+18.36%
— (Cat Avg.)
5 Years
+12.95%
— (Cat Avg.)
Since Inception
+15.28%
— (Cat Avg.)
| Equity | ₹199.49 Cr | 99.93% |
| Others | ₹0.13 Cr | 0.07% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹20.04 Cr | 10.45% |
| Divi's Laboratories Ltd | Equity | ₹13.61 Cr | 7.09% |
| Eli Lilly and Co | Equity | ₹12.39 Cr | 6.46% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹10.08 Cr | 5.25% |
| Johnson & Johnson | Equity | ₹8.53 Cr | 4.45% |
| Laurus Labs Ltd | Equity | ₹8.52 Cr | 4.44% |
| Torrent Pharmaceuticals Ltd | Equity | ₹8.39 Cr | 4.38% |
| Cipla Ltd | Equity | ₹8.33 Cr | 4.34% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹8.04 Cr | 4.19% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.57 Cr | 3.95% |
| AbbVie Inc | Equity | ₹6.18 Cr | 3.22% |
| Lupin Ltd | Equity | ₹5.69 Cr | 2.97% |
| Aurobindo Pharma Ltd | Equity | ₹5.31 Cr | 2.77% |
| Merck & Co Inc | Equity | ₹4.8 Cr | 2.50% |
| Fortis Healthcare Ltd | Equity | ₹4.63 Cr | 2.41% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹4.04 Cr | 2.11% |
| Novartis AG ADR | Equity | ₹3.49 Cr | 1.82% |
| Thermo Fisher Scientific Inc | Equity | ₹3.36 Cr | 1.75% |
| Ipca Laboratories Ltd | Equity | ₹3.3 Cr | 1.72% |
| Mankind Pharma Ltd | Equity | ₹3.17 Cr | 1.65% |
| Amgen Inc | Equity | ₹3.04 Cr | 1.59% |
| Biocon Ltd | Equity | ₹2.83 Cr | 1.47% |
| Alkem Laboratories Ltd | Equity | ₹2.65 Cr | 1.38% |
| Gland Pharma Ltd | Equity | ₹2.64 Cr | 1.37% |
| Zydus Lifesciences Ltd | Equity | ₹2.63 Cr | 1.37% |
| Gilead Sciences Inc | Equity | ₹2.48 Cr | 1.29% |
| Abbott Laboratories | Equity | ₹2.3 Cr | 1.20% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹1.99 Cr | 1.04% |
| Ajanta Pharma Ltd | Equity | ₹1.94 Cr | 1.01% |
| Intuitive Surgical Inc | Equity | ₹1.93 Cr | 1.01% |
| Danaher Corp | Equity | ₹1.89 Cr | 0.98% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.78 Cr | 0.93% |
| Novo Nordisk AS ADR | Equity | ₹1.63 Cr | 0.85% |
| Medtronic PLC | Equity | ₹1.48 Cr | 0.77% |
| Global Health Ltd | Equity | ₹1.35 Cr | 0.70% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.34 Cr | 0.70% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.29 Cr | 0.67% |
| Stryker Corp | Equity | ₹1.27 Cr | 0.66% |
| Wockhardt Ltd | Equity | ₹1.18 Cr | 0.62% |
| Regeneron Pharmaceuticals Inc | Equity | ₹1.05 Cr | 0.55% |
| Anthem Biosciences Ltd | Equity | ₹1.05 Cr | 0.55% |
| Becton Dickinson & Co | Equity | ₹0.66 Cr | 0.34% |
| Agilent Technologies Inc | Equity | ₹0.65 Cr | 0.34% |
| IQVIA Holdings Inc | Equity | ₹0.6 Cr | 0.31% |
| Waters Corp | Equity | ₹0.58 Cr | 0.30% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.2 Cr | 0.10% |
| Net Receivables/(Payables) | Cash - Collateral | ₹-0.07 Cr | 0.04% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
31.51%
Mid Cap Stocks
34.40%
Small Cap Stocks
2.69%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹191.72 Cr | 99.93% |
Standard Deviation
This fund
12.53%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.91
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
ISIN INF754K01LR3 | Expense Ratio 1.10% | Exit Load No Charges | Fund Size ₹200 Cr | Age 5 years 11 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,32,564 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments